Sangamo Therapeutics (SGMOQ) Share-based Compensation (2010 - 2025)

Sangamo Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at $349000.0 for Q4 2025.

• On a quarterly basis, Share-based Compensation fell 97.02% year-over-year to $349000.0 in Q4 2025; TTM through Dec 2025 was $6.9 million, a 66.68% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 73.65% from the prior year.
• Share-based Compensation retreated to $349000.0 in Q4 2025 per SGMOQ's latest filing, from $2.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $21.6 million in Q3 2022 and bottomed at -$21.3 million in Q4 2022.
• The 5-year median for Share-based Compensation is $2.2 million (2025), against an average of $3.2 million.
• Across the five-year window, Share-based Compensation soared 35470.45% in 2021 and tumbled 363.77% in 2022, its largest moves.
• Year by year, Share-based Compensation stood at $8.1 million in 2021, then tumbled by 363.77% to -$21.3 million in 2022, then gained by 7.26% to -$19.8 million in 2023, then soared by 159.21% to $11.7 million in 2024, then slumped by 97.02% to $349000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Share-based Compensation figures stand at $349000.0 (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025).